email article
Fewer than 40% of patients with chronic lymphocytic leukemia (CLL) had an adequate immune response to two doses of the Pfizer/BioNTech COVID-19 vaccine, a prospective study showed.
Overall, 39.5% of 167 patients with CLL had adequate antibody levels after the second vaccine dose. A matched comparison of a subgroup of patients with CLL and a group of healthy individuals showed that half of the patients with leukemia responded to the vaccine as compared with all of the healthy controls.
Vaccine response rates in the patients with CLL ranged from 79.2% for those who had a clinical remission after antileukemic therapy to 16% for patients who were vaccinated during treatment. Patients who had yet to be treated had an antibody response rate of 55.2%, reported Yair Herishanu, MD, of the Tel Aviv Sourasky Medical Center in Israel, and colleagues in
Share this article
WASHINGTON, April 16, 2021 /PRNewswire/ Two new studies published in
Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer. According to researchers, these studies could help inform the ideal time for vaccination of these populations.
Study suggests two-dose COVID-19 vaccine is less effective for people with CLL as compared to healthy controls
The first study reports that people with CLL had markedly lower immune response rates to the two-dose mRNA COVID-19 vaccine than healthy individuals of the same age. Because clinical trials of these vaccines did not include patients with blood cancers, who are at high risk of severe illness and complications from the virus, gauging the effectiveness of the vaccine in this population is critically important.
Studies Suggest People with Blood Cancers May Not Be Optimally Protected after COVID-19 Vaccination prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.